HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD. Financials Hainan Huluwa Pharmaceutical Group Co., Ltd.
Equities
605199
CNE100004223
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.82 CNY | -0.08% |
|
-0.76% | -22.03% |
| May. 01 | Huluwa Pharmaceutical Gets Nod to Register Two Drugs | MT |
| Apr. 26 | Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 9,651 | 9,971 | 6,410 | 6,066 |
| Enterprise Value (EV) 1 | 9,588 | 9,982 | 6,613 | 6,825 |
| P/E ratio | 75.4 x | 138 x | 76.3 x | 56.1 x |
| Yield | 0.62% | - | - | - |
| Capitalization / Revenue | 8.31 x | 7.37 x | 4.23 x | 3.18 x |
| EV / Revenue | 8.25 x | 7.37 x | 4.37 x | 3.58 x |
| EV / EBITDA | 66.7 x | 85.3 x | 46.2 x | 37.5 x |
| EV / FCF | -74.2 x | -190 x | -32.1 x | -13 x |
| FCF Yield | -1.35% | -0.53% | -3.12% | -7.67% |
| Price to Book | 10.5 x | 10.7 x | 6.32 x | 5.41 x |
| Nbr of stocks (in thousands) | 400,109 | 400,109 | 400,109 | 400,109 |
| Reference price 2 | 24.12 | 24.92 | 16.02 | 15.16 |
| Announcement Date | 4/16/21 | 4/28/22 | 4/17/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 983.8 | 1,306 | 1,162 | 1,354 | 1,515 | 1,905 |
| EBITDA 1 | 146.2 | 162.7 | 143.7 | 117 | 143.1 | 181.8 |
| EBIT 1 | 110.6 | 121.2 | 100.6 | 72.7 | 97.52 | 130.2 |
| Operating Margin | 11.25% | 9.28% | 8.66% | 5.37% | 6.44% | 6.83% |
| Earnings before Tax (EBT) 1 | 118.5 | 142.2 | 134.4 | 81.66 | 97.23 | 135.5 |
| Net income 1 | 100.5 | 120.3 | 121.5 | 72.14 | 85.68 | 106.5 |
| Net margin | 10.22% | 9.21% | 10.46% | 5.33% | 5.66% | 5.59% |
| EPS 2 | 0.3000 | 0.3300 | 0.3200 | 0.1800 | 0.2100 | 0.2700 |
| Free Cash Flow 1 | -112.5 | 26.16 | -129.2 | -52.48 | -206.3 | -523.4 |
| FCF margin | -11.44% | 2% | -11.12% | -3.88% | -13.62% | -27.47% |
| FCF Conversion (EBITDA) | - | 16.07% | - | - | - | - |
| FCF Conversion (Net income) | - | 21.74% | - | - | - | - |
| Dividend per Share | - | 0.2250 | 0.1500 | - | - | - |
| Announcement Date | 6/6/19 | 6/23/20 | 4/16/21 | 4/28/22 | 4/17/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 11.5 | 204 | 759 |
| Net Cash position 1 | 39.4 | 1.47 | 62.9 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 0.0986 x | 1.423 x | 4.174 x |
| Free Cash Flow 1 | -113 | 26.2 | -129 | -52.5 | -206 | -523 |
| ROE (net income / shareholders' equity) | 21% | 19.3% | 15.6% | 7.53% | 8.71% | 10.4% |
| ROA (Net income/ Total Assets) | 7.28% | 6.96% | 4.82% | 2.77% | 2.99% | 3.03% |
| Assets 1 | 1,381 | 1,730 | 2,521 | 2,605 | 2,863 | 3,515 |
| Book Value Per Share 2 | 1.680 | 1.790 | 2.290 | 2.320 | 2.530 | 2.800 |
| Cash Flow per Share 2 | 0.5000 | 0.4300 | 0.8600 | 1.220 | 1.200 | 1.310 |
| Capex 1 | 72.8 | 58.4 | 59.4 | 138 | 392 | 489 |
| Capex / Sales | 7.4% | 4.47% | 5.11% | 10.17% | 25.9% | 25.68% |
| Announcement Date | 6/6/19 | 6/23/20 | 4/16/21 | 4/28/22 | 4/17/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -22.03% | 654M | |
| +37.41% | 705B | |
| +32.40% | 583B | |
| -3.07% | 364B | |
| +20.39% | 332B | |
| +5.59% | 291B | |
| +16.72% | 238B | |
| -3.44% | 210B | |
| +10.45% | 209B | |
| +9.39% | 169B |
- Stock Market
- Equities
- 605199 Stock
- Financials Hainan Huluwa Pharmaceutical Group Co., Ltd.
